This case highlights that methyl-CCNU can induce pulmonary fibrosis even at low cumulative doses.
Answers are grounded in this paper and cite their sources.
Pulmonary fibrosis may occur at lower methyl-CCNU doses than recognized; case report leaves open need for prospective confirmation.
Pulmonary fibrosis is a serious side effect of nitrosourea therapy, occurring most frequently in patients treated with BCNU. Pulmonary fibrosis developed in a 63 year-old male patient while being treated with adjuvant methyl-CCNU for rectal carcinoma. This toxicity is rare with methyl-CCNU, having only been reported once previously. The case of methyl-CCNU-induced pulmonary fibrosis reported here occurred at a much lower total dose than the first reported case (604 mg/m2 vs. 2,733 mg/m2). Details of the case history, including radiographic and pathologic findings, are presented.
No takes yet. Share an insight, caveat, or question.
Block et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: